Ontology highlight
ABSTRACT:
SUBMITTER: Khatri A
PROVIDER: S-EPMC6852105 | biostudies-literature | 2019 Dec
REPOSITORIES: biostudies-literature
Journal of clinical pharmacology 20190630 12
Risankizumab, a humanized monoclonal antibody that targets interleukin-23 p19 subunit, was developed for the treatment of psoriasis. This work characterizes risankizumab pharmacokinetics in Japanese and Chinese healthy subjects compared with white healthy subjects and in Japanese patients with moderate to severe plaque psoriasis, generalized pustular psoriasis, or erythrodermic psoriasis. A phase 1, single-dose study evaluated risankizumab pharmacokinetics and safety/tolerability in healthy whit ...[more]